Design Therapeutics (DSGN) Times Interest Earned (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Times Interest Earned of -$6.89 for Q2 2026, up 12.54% year-over-year from -$6.12 in Q2 2025, and down 17.29% on a QoQ basis from -$5.87 in Q1 2026.
Design Therapeutics (DSGN) Times Interest Earned (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Times Interest Earned for 7 years, with the latest figure at -$6.89 in Q2 2026.
- Times Interest Earned for Q2 2026 came in at -$6.89, up 12.54% year-over-year; the trailing twelve-month figure through Jun 2026 was -$7.62 (down 3.64% YoY), and the FY2025 annual result was -$0.0, up 53.41% from the prior year.
- Times Interest Earned retreated to -$6.89 in Q2 2026, from -$5.87 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.0 in Q4 2022 and troughed at -$8.51 in Q3 2025.
- A 5-year average of -$5.51 and a median of -$6.1 in 2024 frame the typical range for Times Interest Earned.
- The widest annual swing landed in 2023, when Times Interest Earned tumbled 19255.04%; it then grew 26.93% in 2026.
- A 5-year view of Times Interest Earned shows it stood at -$0.0 in 2022, then tumbled by 19255.04% to -$0.36 in 2023, then slumped by 1676.66% to -$6.33 in 2024, then tumbled by 31.29% to -$8.31 in 2025, then increased by 17.14% to -$6.89 in 2026.
- Per Business Quant data, the three most recent Times Interest Earned figures were -$6.89 in Q2 2026, -$5.87 in Q1 2026, and -$8.31 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | -6.89 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.89 |
| Mar 31, 2026 | -5.87 |
| Dec 31, 2025 | -8.31 |
| Sep 30, 2025 | -8.51 |
| Jun 30, 2025 | -7.87 |
| Mar 31, 2025 | -8.04 |
| Dec 31, 2024 | -6.33 |
| Sep 30, 2024 | -7.15 |
| Jun 30, 2024 | -6.82 |
| Mar 31, 2024 | -6.56 |
| Dec 31, 2023 | -0.36 |
| Sep 30, 2023 | -14.66 |
| Jun 30, 2023 | -11.27 |
| Mar 31, 2023 | -5.19 |
| Dec 31, 2022 | -12.77 |
| Sep 30, 2022 | -4.97 |
| Jun 30, 2022 | -3.24 |
| Mar 31, 2022 | -10.11 |
| Sep 30, 2021 | -2.45 |
| Jun 30, 2021 | -1.64 |